N
INBX

Nuveen’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Nuveen’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-82,829
Closed -$2.9M – 3486
2024
Q1 		$2.9M Sell
82,829
-1,182
-1% -$43.1K ﹤0.01% 2232
2023
Q4 		$3.19M Sell
84,011
-5,252
-6% -$113K ﹤0.01% 2188
2023
Q3 		$1.64M Sell
89,263
-274
-0.3% -$5.73K ﹤0.01% 2376
2023
Q2 		$2.32M Buy
89,537
+843
+1% +$19.7K ﹤0.01% 2280
2023
Q1 		$1.67M Buy
88,694
+40
+0% +$930 ﹤0.01% 2410
2022
Q4 		$2.19M Sell
88,654
-26,262
-23% -$772K ﹤0.01% 2353
2022
Q3 		$2.06M Sell
114,916
-491
-0.4% -$8.85K ﹤0.01% 2388
2022
Q2 		$1.31M Buy
115,407
+32,388
+39% +$476K ﹤0.01% 2670
2022
Q1 		$1.9M Buy
83,019
+1,019
+1% +$26K ﹤0.01% 2530
2021
Q4 		$3.13M Sell
82,000
-6,676
-8% -$267K ﹤0.01% 2355
2021
Q3 		$3.28M Sell
88,676
-7,904
-8% -$241K ﹤0.01% 2435
2021
Q2 		$2.66M Buy
96,580
+66,960
+226% +$1.39M ﹤0.01% 2571
2021
Q1 		$595K Sell
29,620
-3,198
-10% -$93.4K ﹤0.01% 3059
2020
Q4 		$1.08M Buy
+32,818
New +$873K ﹤0.01% 2774

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Nuveen's INBX Position: Q2 2024 in Review

Nuveen sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 82,829 shares — an estimated $2.9M sold.

Nuveen first reported a position in INBX in Q4 2020 and held it in 14 quarters. The position peaked at $3.28M in Q3 2021. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Nuveen reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 82,829 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $2.9M.
  • Nuveen first reported a position in Inhibrx, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Nuveen's Inhibrx, Inc. Common Stock position peaked at $3.28M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.